Sign in
Active, not recruitingNo phase

A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation

Key facts

Who runs it
Boston Scientific Corporation
Where
New York, The Bronx, and Tucson, United StatesSee the 3 sitesAlso in 1 other country, 1 site
Trial code
Status
Active, not recruiting
People taking part
4 people enrolled
Started
13 Nov 2019
Expected to end
Nov 2026
Type of study
Interventional
Treatments tested
  • Millipede Transcatheter Annuloplasty Ring System (Millipede System)
Record updated
23 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (34)Hide the full registry criteria

Who can take part

  • Subject is 18 years of age or older
  • Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed
  • Subject has moderate to severe (3+) or severe (4+) functional mitral regurgitation confirmed by echocardiography core lab
  • Subject is symptomatic (NYHA Class II-IV) despite guideline directed medical therapy, including CRT if indicated
  • The local site heart team concurs that mitral valve surgery will not be offered as a first-line treatment option
  • Subject is a candidate for annuloplasty based on the criteria below as assessed by the investigative site (and confirmed by the Case Review Committee [CRC]):; Left Ventricular Ejection Fraction (LVEF) ≥ 25% Left Ventricular End Diastolic Diameter (LVEDD) ≤ 65 mm Coaptation distance (i.e. tenting height) < 10 mm Absence of posterior wall aneurysm

Who cannot take part

  • Subject is on the waiting list for a transplant or has had a prior heart transplant
  • Subject has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 30 days prior to study enrollment
  • Subject has had any percutaneous coronary, carotid, or other endovascular intervention within 30 days prior to study enrollment
  • Subject has had carotid surgery within 30 days prior to study enrollment
  • Subject has had any open coronary or vascular surgery (other than carotid surgery) within 3 months prior to study enrollment
  • Subject has had a cardiac resynchronization therapy (CRT) device implantation within 3 months prior to study enrollment
  • Need for emergent or urgent surgery for any reason
  • Subject has a prior history of atrial septal defect (ASD) closure or patient foramen ovale (PFO) closure
  • Subject is participating in another investigational drug or device study that has not reached its primary endpoint or subject intends to participate in another investigational device clinical trial within 12 months after index procedure
  • Subject has untreated clinically significant coronary artery disease requiring revascularization
  • Any planned cardiac surgery within the next 12 months
  • Subject has physical evidence of right-sided congestive heart failure (CHF) with echocardiographic evidence of moderate or severe right ventricular dysfunction and/or severe tricuspid valve regurgitation
  • Subject has the presence of prosthetic heart valve in any position
  • Subject has known hypersensitivity or contraindication to protocol required procedural or post procedural medication (e.g., anticoagulation therapy) or hypersensitivity to nickel or titanium
  • Subject has known hypersensitivity to contrast that cannot be adequately premedicated
  • Subject has a history of endocarditis within 6 months of index procedure or evidence of an active systemic infection or sepsis
  • Subject has oxygen-dependent chronic obstructive pulmonary disease
  • Subject has documented severe liver disease
  • Subject has renal insufficiency (eGFR <20mL/min) and is not on dialysis
  • Subject has Hgb <8 g/dL, platelet count <50,000 cells/mm3 or >700,000 cells/mm3, or white blood cell count <1,000 cells/mm3
  • Subject has severe calcification of the mitral annulus or leaflets or other anatomic features that make the subject unsuitable for annuloplasty with the Millipede System in the judgment of the treating physician or subject does not have suitable mitral annular diameter (determined by CT) as per the Instructions for Use
  • Transfemoral venous and transseptal access determined not to be feasible
  • Subject has severe aortic valve stenosis and/or aortic valve regurgitation
  • Subject has a life expectancy less than 12 months
  • Subjects in whom trans-esophageal echocardiography-Doppler assessment is contraindicated or in which mitral regurgitation is not measurable by Transthoracic Echocardiography (TTE)
  • Subject has fixed pulmonary artery systolic pressure > 70 mmHG
  • Female subject who is breast feeding or is pregnant and planning to become pregnant within the study period
  • Subject has any evidence of intracardiac thrombus

Where in United States

Also in 1 other country, 1 site

  • Columbia University Medical Center/New York-Presbyterian HospitalNew York, United States
  • Montefiore Medical CenterThe Bronx, United States
  • Tucson Medical Center HealthcareTucson, United States

About the trial

What the trial wants to find out

To evaluate the feasibility and safety of the Millipede Transcatheter Annuloplasty Ring System in subjects with functional mitral regurgitation

The group in the trial

  • Mitral Valve RepairTreatment being tested

    All subjects will receive mitral valve repair using the Millipede System

    Treatment: Millipede Transcatheter Annuloplasty Ring System (Millipede System)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Study to Evaluate the Feasibility and Safety of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation: (Millipede Feasibility Study)
Record updated
23 October 2026